Lillia Steffenson, Alex Roszman, Cameron Wallace, Taylor Corbin Kot, Clay Spitler, Patrick Bergin, Michael Githens, Justin Haller
{"title":"Predictors of Reoperation in Induced Membrane Technique for Acute Traumatic Bone Loss.","authors":"Lillia Steffenson, Alex Roszman, Cameron Wallace, Taylor Corbin Kot, Clay Spitler, Patrick Bergin, Michael Githens, Justin Haller","doi":"10.1097/BOT.0000000000003024","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To identify patient, injury, and surgical characteristics associated with success or failure of Masquelet's induced membrane technique (IMT) for acute traumatic bone loss.</p><p><strong>Methods: </strong>Design: Retrospective cohort study.</p><p><strong>Setting: </strong>Four Level 1 Academic Trauma Centers.</p><p><strong>Patients selection criteria: </strong>Patients acutely treated with IMT for AO/OTA 32, 33, and 41-43 fractures with bone loss at four Level 1 trauma centers between 2010-2020.</p><p><strong>Outcome measure and comparisons: </strong>Primary outcome was fracture union with comparison between union after initial two stage IMT versus patients who underwent reoperation to promote union or experienced treatment failure defined as: amputation, implant dependent, or persistent nonunion. Variables of interest included demographic variables, injury characteristics, and differences in surgical management (definitive fixation construct, autograft source, use of graft adjuvants).</p><p><strong>Results: </strong>130 fractures with defects were treated with IMT, including 72 tibial fractures and 58 femoral fractures with an average defect length of 6.4cm. Average age of patients was 40 years (range 16 to 68 years) and 65 percent of patients were male. Demographic characteristics including age, sex, BMI, tobacco and alcohol use were not significantly different among treatment outcomes (p >.05). Initial success after two stage IMT was 57.7% (75/130) and 82% (107/130) after subsequent reoperation. Increasing defect length was associated with failure of IMT (mean 5.4 vs 8.3cm, p=.03). Deep infection after stage 2 surgery was associated with reoperation to promote union and treatment failure (p<.01).</p><p><strong>Conclusions: </strong>In this study of acute traumatic bone loss, shorter defect length and absence of infection were significantly associated with success of IMT. Meanwhile fixation construct and autograft choice were not associated with treatment outcome.</p><p><strong>Level of evidence: </strong>III retrospective comparative cohort series.</p>","PeriodicalId":16644,"journal":{"name":"Journal of Orthopaedic Trauma","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Orthopaedic Trauma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/BOT.0000000000003024","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To identify patient, injury, and surgical characteristics associated with success or failure of Masquelet's induced membrane technique (IMT) for acute traumatic bone loss.
Methods: Design: Retrospective cohort study.
Setting: Four Level 1 Academic Trauma Centers.
Patients selection criteria: Patients acutely treated with IMT for AO/OTA 32, 33, and 41-43 fractures with bone loss at four Level 1 trauma centers between 2010-2020.
Outcome measure and comparisons: Primary outcome was fracture union with comparison between union after initial two stage IMT versus patients who underwent reoperation to promote union or experienced treatment failure defined as: amputation, implant dependent, or persistent nonunion. Variables of interest included demographic variables, injury characteristics, and differences in surgical management (definitive fixation construct, autograft source, use of graft adjuvants).
Results: 130 fractures with defects were treated with IMT, including 72 tibial fractures and 58 femoral fractures with an average defect length of 6.4cm. Average age of patients was 40 years (range 16 to 68 years) and 65 percent of patients were male. Demographic characteristics including age, sex, BMI, tobacco and alcohol use were not significantly different among treatment outcomes (p >.05). Initial success after two stage IMT was 57.7% (75/130) and 82% (107/130) after subsequent reoperation. Increasing defect length was associated with failure of IMT (mean 5.4 vs 8.3cm, p=.03). Deep infection after stage 2 surgery was associated with reoperation to promote union and treatment failure (p<.01).
Conclusions: In this study of acute traumatic bone loss, shorter defect length and absence of infection were significantly associated with success of IMT. Meanwhile fixation construct and autograft choice were not associated with treatment outcome.
Level of evidence: III retrospective comparative cohort series.
目的:确定与Masquelet诱导膜技术(IMT)治疗急性外伤性骨丢失的成功或失败相关的患者、损伤和手术特征。方法:设计:回顾性队列研究。设置:四个一级学术创伤中心。患者选择标准:2010-2020年间在4个一级创伤中心接受IMT治疗AO/OTA 32、33和41-43骨折伴骨质流失的患者。结果测量和比较:主要结果是骨折愈合,比较初始两期IMT后的愈合与再次手术以促进愈合或经历治疗失败的患者的愈合,治疗失败定义为:截肢、依赖植入物或持续不愈合。感兴趣的变量包括人口统计学变量、损伤特征和手术处理的差异(确定固定结构、自体移植物来源、移植物佐剂的使用)。结果:IMT治疗缺损骨折130例,其中胫骨骨折72例,股骨骨折58例,平均缺损长度6.4cm。患者的平均年龄为40岁(16 - 68岁),65%的患者为男性。人口统计学特征包括年龄、性别、体重指数、吸烟和饮酒在治疗结果之间无显著差异(p < 0.05)。二期IMT术后的初始成功率为57.7%(75/130),术后再手术成功率为82%(107/130)。缺陷长度增加与IMT失败相关(平均5.4 cm vs 8.3cm, p=.03)。2期手术后深度感染与再手术促进愈合和治疗失败相关(结论:在本研究中,急性外伤性骨丢失,较短的缺损长度和没有感染与IMT的成功显著相关。同时,固定结构和自体移植物的选择与治疗结果无关。证据水平:III回顾性比较队列研究。
期刊介绍:
Journal of Orthopaedic Trauma is devoted exclusively to the diagnosis and management of hard and soft tissue trauma, including injuries to bone, muscle, ligament, and tendons, as well as spinal cord injuries. Under the guidance of a distinguished international board of editors, the journal provides the most current information on diagnostic techniques, new and improved surgical instruments and procedures, surgical implants and prosthetic devices, bioplastics and biometals; and physical therapy and rehabilitation.